Pioglitazone (PIO), of the thiazolidinedione class, is an agonist of peroxisome proliferator-activated receptors (PPARs) and improves hyperglycemia, reduces hyperinsulinemia and enhances β-cell function in a variety of insulin-resistant animal models [35,36]. The gene discussed is INS; the disease is Hyperinsulinemia.